NeuroPace, Inc. (NPCE)
After hours:
| Previous close | 12.99 |
| Open | 12.82 |
| Bid | 13.72 x 100 |
| Ask | 14.12 x 100 |
| Day's range | 12.69 - 14.14 |
| 52-week range | 3.80 - 18.15 |
| Volume | |
| Avg. volume | 109,352 |
| Market cap | 401.216M |
| Beta (5Y monthly) | 2.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may d
- GlobeNewswire
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Monday, April 8 at 3:45pm ET, and management will participate in one-on-one meetings with investors during
- GlobeNewswire
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue guidance of between $73-$77 million -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported
